Literature DB >> 10428907

Construction and characterization of mutants of the TEM-1 beta-lactamase containing amino acid substitutions associated with both extended-spectrum resistance and resistance to beta-lactamase inhibitors.

P D Stapleton1, K P Shannon, G L French.   

Abstract

Extended-spectrum TEM beta-lactamases (ESBLs) do not usually confer resistance to beta-lactamase inhibitors such as clavulanate or tazobactam. To investigate the compatibility of the two phenotypes we used site-directed mutagenesis of the bla(TEM-1) gene to introduce into the TEM-1 beta-lactamase amino acid substitutions that confer the ESBL phenotype: TEM-12 (Arg164-->Ser), TEM-26 (Arg164-->Ser plus Glu104-->Lys), TEM-19 (Gly238-->Ser), and TEM-15 (Gly238-->Ser plus Glu104-->Lys). These were combined with three sets of substitutions that confer inhibitor resistance: TEM-31 (Arg244-->Cys), TEM-33 (Met69-->Leu), and TEM-35 (Met69-->Leu and Asn276-->Asp). Introduction of the Arg244-->Cys substitution gave rise to inhibitor-resistant hybrid enzymes that either lost ESBL activity (TEM-12, TEM-15, and TEM-19) or had reduced activity (TEM-26) against ceftazidime. In contrast, the introduction of Met69-->Leu or Met69-->Leu plus Asn276-->Asp substitutions did not significantly affect the abilities of the enzymes to confer resistance to ceftazidime, although increased susceptibility to cefotaxime was observed with Escherichia coli strains that expressed the TEM-19 and TEM-26 beta-lactamases. With the exception of the TEM-12 beta-lactamase, introduction of the Met69-->Leu substitution did not give rise to enzymes with increased resistance to clavulanate compared to that of the TEM-1 beta-lactamase. However, introduction of the double substitution Met69-->Leu plus Asn276-->Asp in the ESBLs did give rise to low-level (TEM-19, TEM-15, and TEM-26) or moderate-level (TEM-12) clavulanate resistance. None of the hybrid enzymes were as resistant to clavulanate as the corresponding inhibitor-resistant TEM beta-lactamase mutant, suggesting that active-site configuration in the ESBLs limits the degree of clavulanate resistance conferred.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10428907      PMCID: PMC89385     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  31 in total

1.  Inhibitor-resistant TEM (IRT) beta-lactamases with different substitutions at position 244.

Authors:  L Bret; E B Chaibi; C Chanal-Claris; D Sirot; R Labia; J Sirot
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

2.  Implication of Ile-69 and Thr-182 residues in kinetic characteristics of IRT-3 (TEM-32) beta-lactamase.

Authors:  S Farzaneh; E B Chaibi; J Peduzzi; M Barthelemy; R Labia; J Blazquez; F Baquero
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

3.  Characterization of an inhibitor-resistant enzyme IRT-2 derived from TEM-2 beta-lactamase produced by Proteus mirabilis strains.

Authors:  L Bret; C Chanal; D Sirot; R Labia; J Sirot
Journal:  J Antimicrob Chemother       Date:  1996-08       Impact factor: 5.790

4.  Are TEM beta-lactamases encoded by pBR322 and Bluescript plasmids enzymatically indistinguishable?

Authors:  E B Chaibi; J Peduzzi; M Barthelemy; R Labia
Journal:  J Antimicrob Chemother       Date:  1997-05       Impact factor: 5.790

5.  Construction and characterization of an OHIO-1 beta-lactamase bearing Met69Ile and Gly238Ser mutations.

Authors:  R A Bonomo; J R Knox; S D Rudin; D M Shlaes
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

6.  A complex mutant of TEM-1 beta-lactamase with mutations encountered in both IRT-4 and extended-spectrum TEM-15, produced by an Escherichia coli clinical isolate.

Authors:  D Sirot; C Recule; E B Chaibi; L Bret; J Croize; C Chanal-Claris; R Labia; J Sirot
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

7.  Incidence and mechanisms of resistance to the combination of amoxicillin and clavulanic acid in Escherichia coli.

Authors:  P Stapleton; P J Wu; A King; K Shannon; G French; I Phillips
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

Review 8.  Extended-spectrum and inhibitor-resistant TEM-type beta-lactamases: mutations, specificity, and three-dimensional structure.

Authors:  J R Knox
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

Review 9.  beta-Lactamases in laboratory and clinical resistance.

Authors:  D M Livermore
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

10.  Molecular characterization of nine different types of mutants among 107 inhibitor-resistant TEM beta-lactamases from clinical isolates of Escherichia coli.

Authors:  C Henquell; C Chanal; D Sirot; R Labia; J Sirot
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

View more
  11 in total

1.  Mutant TEM beta-lactamase producing resistance to ceftazidime, ampicillins, and beta-lactamase inhibitors.

Authors:  Sergei Vakulenko; Dasantila Golemi
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

Review 2.  Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat.

Authors:  P A Bradford
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

3.  Resistance to beta-lactamase inhibitor protein does not parallel resistance to clavulanic acid in TEM beta-lactamase mutants.

Authors:  William A Schroeder; Troy R Locke; Susan E Jensen
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

4.  Combining computational and experimental screening for rapid optimization of protein properties.

Authors:  Robert J Hayes; Jorg Bentzien; Marie L Ary; Marian Y Hwang; Jonathan M Jacinto; Jöst Vielmetter; Anirban Kundu; Bassil I Dahiyat
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-21       Impact factor: 11.205

5.  Experimental evolution of gene duplicates in a bacterial plasmid model.

Authors:  Alisha K Holloway; Timothy Palzkill; James J Bull
Journal:  J Mol Evol       Date:  2007-01-08       Impact factor: 2.395

6.  Mutational events in cefotaximase extended-spectrum beta-lactamases of the CTX-M-1 cluster involved in ceftazidime resistance.

Authors:  Angela Novais; Rafael Cantón; Teresa M Coque; Andrés Moya; Fernando Baquero; Juan Carlos Galán
Journal:  Antimicrob Agents Chemother       Date:  2008-04-28       Impact factor: 5.191

7.  Analysis of the plasticity of location of the Arg244 positive charge within the active site of the TEM-1 beta-lactamase.

Authors:  David C Marciano; Nicholas G Brown; Timothy Palzkill
Journal:  Protein Sci       Date:  2009-10       Impact factor: 6.725

8.  Negative Epistasis and Evolvability in TEM-1 β-Lactamase--The Thin Line between an Enzyme's Conformational Freedom and Disorder.

Authors:  Eynat Dellus-Gur; Mikael Elias; Emilia Caselli; Fabio Prati; Merijn L M Salverda; J Arjan G M de Visser; James S Fraser; Dan S Tawfik
Journal:  J Mol Biol       Date:  2015-05-22       Impact factor: 5.469

9.  In vitro selection of variants resistant to beta-lactams plus beta-lactamase inhibitors in CTX-M beta-lactamases: predicting the in vivo scenario?

Authors:  Aida Ripoll; Fernando Baquero; Angela Novais; Mario J Rodríguez-Domínguez; Maria-Carmen Turrientes; Rafael Cantón; Juan-Carlos Galán
Journal:  Antimicrob Agents Chemother       Date:  2011-07-25       Impact factor: 5.191

10.  Genetic and structural characterization of an L201P global suppressor substitution in TEM-1 beta-lactamase.

Authors:  David C Marciano; Jeanine M Pennington; Xiaohu Wang; Jian Wang; Yu Chen; Veena L Thomas; Brian K Shoichet; Timothy Palzkill
Journal:  J Mol Biol       Date:  2008-09-16       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.